Global Pharmaceutical Contract Manufacturing Organization (CMO) Market Size study & Forecast, by Service Type (Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing) and Regional Analysis, 20

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market Size study & Forecast, by Service Type (Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing) and Regional Analysis, 2022-2029

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Contract manufacturing is outsourcing where a manufacturer enters a formal agreement with another manufacturing company for its parts, goods, or components. A contract manufacturing organization (CMO) is an organization that caters to the pharmaceutical sector and offers clients entire services from manufacturing to drug research. CMOs provide services ranging from drug development, manufacturing, packaging, labeling, and distribution to their clients. Pharmaceutical clients can extend their technical resources by outsourcing to a CMO without incurring more overhead. By concentrating on core capabilities and high-value projects while decreasing or not increasing infrastructure or technical people, the client may manage its internal resources and costs. The business controls internal costs and resources by concentrating on core skills and high-value initiatives while decreasing or not increasing infrastructure or technical staff. The market growth is primarily driven by the factors such as surging demand for generic drugs, rising outsourcing volume by pharmaceutical companies, and increasing prevalence of various diseases.

In addition, the growing investment in research and development activities across the pharmaceutical industry is playing a significant role in market growth across the globe. As per Statista, in 2020, the total overall R&D spending in the pharmaceutical sector accounted for USD 198 billion and it is projected to reach around USD 248 billion by the year 2025. Consequentially, these aforementioned factors are propelling the market’s development globally. Moreover, the rising number of government initiatives, as well as expansion in emerging countries are presenting various lucrative opportunities over the forecasting years. However, the stringent regulatory requirements and increasing lead time and logistics costs are challenging the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Pharmaceutical Contract Manufacturing Organization (CMO) Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the rising number of clinical trials in the region, along with the presence of advanced manufacturing capabilities. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as favorable government policies, growing investment in R&D, as well as rising outsourcing volume by pharmaceutical companies in the market space.

Major market players included in this report are:
Catalent Inc.
Recipharm AB
Jubilant Biosys Ltd. (Jubilant Pharmova Ltd)
Patheon Inc. (Thermo Fisher Scientific Inc.)
Boehringer Ingelheim Group
Pfizer CentreSource (Pfizer Inc.)
Aenova Group
Famar SA
Baxter Biopharma Solutions (Baxter International Inc.)
Lonza Group AG

Recent Developments in the Market:
In March 2022, Sterling Drug Solutions UK, a global CDMO, and Novartis announced an agreement for Sterling to purchase Novartis' Ringaskiddy campus (formerly known as Novartis Ringaskiddy Limited) in Ireland. The company acquired the 111-acre site that involves three active pharmaceutical ingredient (API) manufacturing buildings, along with facilities to support the development and scale-up in line with Sterling’s core business focus.
In March 2022, Lonza completed a laboratory expansion project at its API manufacturing facility in Nansha, China. The upgrades increase the development laboratories' capacity and capabilities while enabling kilogram-scale production of highly potent APIs (HPAPIs), which have grown to play a significant role in the company's small-molecule development pipeline.

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Service Type, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Service Type:
Active Pharmaceutical Ingredient (API) Manufacturing
Finished Dosage Formulation (FDF) Development and Manufacturing

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Catalent Inc.
Recipharm AB
Jubilant Biosys Ltd. (Jubilant Pharmova Ltd)
Patheon Inc. (Thermo Fisher Scientific Inc.)
Boehringer Ingelheim Group
Pfizer CentreSource (Pfizer Inc.)
Aenova Group
Famar SA
Baxter Biopharma Solutions (Baxter International Inc.)
Lonza Group AG

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.